br of origin which demonstrated similar results
of origin, which demonstrated similar results as the original cohort (Table S2). Last, less frequent use of rosuvastatin likely resulted in lack of power to detect the statistical difference as above.
A clinical implication of this study is the possible use of a statin to prevent VTE in women with endometrial cancer. Currently, VTE preven-tion is not an approved indication for statin or aspirin use, so effects of these medications on the risk of VTE would need to be confirmed with randomized trials. If this effect persists, the use of certain statins and/ or aspirin may also be cost-effective for VTE prophylaxis in high-risk pa-tients as compared to the current standard prophylactic agent (low-mo-lecular-weight heparin). Effects of concurrent statin and aspirin use on VTE risk reduction is also of interest. Additional studies with improved measurement and closer monitoring of medication use are warranted to address this potential role for statins and/or aspirin in endometrial cancer treatment.
Conflict of interest statement
Honorarium, Chugai Pharmaceutical Co., Ltd. and Astra Zeneca (T.E.); research grant, Pfizer Inc., Yakult Honsha Co., Ltd., and OncoThreapy Science Inc. (K.H.); honorarium, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co.,
Conceptualization: K.M.; Data curation: all authors; Formal analysis:
K.M.; Funding acquisition: K.M., L.D.R.; Investigation: all authors; Meth-
odology: K.M.; Project administration: K.M.; Resources: all; Software:
- original draft: K.M.; Writing - review & editing: all authors.
Ensign Endowment for Gynecologic Cancer Research (K.M.).
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
 R. Lassila, A. Jula, J. Pitkaniemi, J. Haukka, The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study, BMJ Open 4 (2014), e005862. .  F. Lotsch, O. Konigsbrugge, F. Posch, C. Zielinski, I. Pabinger, C. Ay, Statins are associ-ated with low risk of venous thromboembolism in patients with cancer: a prospec-
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/mgene
Nasser Pouladia, , Sepehr Abdolahia, Davoud Farajzadeha, Mohammad Ali Hossein Pour Feizib
a Department of Biology, Azarbaijan Shahid Madani University, Tabriz, Iran
b Department of Animal Biology, Tabriz University, Tabriz, Iran
p53 plays an important role in genome integrity and controls cell proliferation, induces 186689-07-6 arrest, apoptosis, and DNA repair. Various lncRNAs, proteins, and small molecules can influence its activity. WRAP53, which lies in the opposite direction of TP53 on the opposite strand with 5′-5′ overlapping fashion, expressing three diﬀerent transcripts with three alternative start exons. Based on informative values of SNPs in disease incident, studying gene polymorphism might help us to find a prognostic and therapeutic marker. Polymorphisms of TP53 as a major tumor suppressor gene and its overlapping gene, WRAP53, as an important protein in Cajal bodies traﬃcking have been shown to be associated with various cancer susceptibility. In this study, we assess the association of TP53 at codon 72 (R72P), which is a proline-to-arginine substitution, and WRAP53 at codon 68 (R68G), which is a Glycine-to-arginine substitution, with breast cancer susceptibility in-dividually and as a haplotype in the north-west of Iran population. We genotyped two mentioned polymorphisms in 206 cases of breast cancer and 180 controls with PCR-ARMS and PCR-SSCP methods. The results showed no statistically significant correlation of studied variants with breast cancer susceptibility and for the first time, we showed that the haplotype of these two SNPs (R72G68 genotype) has a significant diﬀerence (p-value = 0.02) associated with breast cancer in these patients. In conclusion, the polymorphisms of TP53 at codon 72 and WRAP53 at codon 68 and their haplotype may confer an increased risk of breast cancer in the assessed popu-lation. r> 1. Introduction
1.1. Breast cancer statics and subtypes
Cancer is the second leading cause of death in the United States and breast cancer is the first prevalent cancer in women which 268,670 new cases diagnosed in 2017 among which estimated deaths are 41,400 (Desantis et al., 2017; Siegel et al., 2018). Considering this statics, there is an urgent need to act against the increasing rate of this threat. To do so, we need to find susceptible genetic factors through comprehensive studying the relying reasons. Breast cancer is a heterogeneous disease and by molecular means, divided into four types: Laminal A, which has a good prognosis; Laminal B; HER-2 overexpressing and basal-like cell, which is related to high invasiveness (Reigosa et al., 2016). Several factors such as Age at menarche, parity, age at first birth, breastfeeding, age at menopause, body mass index, family history of breast cancer, alcohol use, use of oral contraceptives, use of menopausal hormone therapy have been proven to have an impact in breast cancer